Analyst Consensus ?
ConsensusBuy22 ratings
Bullish1881.8%
Neutral418.2%
Bearish00.0%
Axon Enterprise, Inc. · AXON · FY2024 Q1 · Calendar Q2 2024
Axon: AI adoption and TASER 10 demand support raised guidance
The current call supports a constructive growth thesis: resilient demand for TASER 10 and cloud services, alongside early Draft One adoption, underpinned raised guidance. The evidence is strongest on current momentum; the next test is converting AI adoption, capacity expansion, and Dedrone integration into sustained results.
Reported After market closeNASDAQIndustrials
$34.15B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.15
Consensus $0.94
EPS surprise
+21.7%
Reported versus consensus
Reported revenue
$460.7M
Consensus $441.6M
Revenue surprise
+4.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-4.6%
Event window
SPY move
+0.1%
Same window
Abnormal move
-4.7%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
-9.8%
Up to 20 sessions
AXONSPY benchmark
Ask FN2 about AXON FY2024 Q1
Transcript, numbers and history already loaded
Why did AXON fall 4.6% after beating EPS estimates in FY2024 Q1?What changed in AXON's guidance and outlook in FY2024 Q1?Give me the bull and bear case for AXON after FY2024 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management reported stronger current-quarter execution, raised full-year revenue guidance, increased capex for TASER 10 capacity, and added a planned Dedrone acquisition. Draft One emerged as a more prominent growth driver, while supply, seasonality, integration, and regulatory risks remain.
Guidance delta
Management raised full-year revenue guidance and increased capex guidance to fund TASER 10 capacity and automation.
Key takeaways
- Management described record revenue and adjusted EBITDA margins, with 34% top-line growth and a 23.6% adjusted EBITDA margin.
- Draft One AI reporting showed rapid traction, while TASER 10 demand remained strong and supported capacity expansion.
- The planned Dedrone acquisition broadens Axon's drone-security offering and international channel reach.
- The main execution questions are AI adoption, TASER 10 supply, acquisition integration, and regulatory constraints on drone operations.
Management priorities
- Scale Draft One AI reporting across customers
- Expand TASER 10 production capacity and automation
- Integrate Dedrone into Software and Sensors
- Grow international channels, especially in EMEA
Follow AXON with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$420.37Current
$300Low
$648.43Average
$900High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Overweight | Maintain | Oct 20, 2026 |
| Argus Research | Buy | Buy | Maintain | Sep 3, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Needham | Buy | Buy | Maintain | Jul 6, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Jun 25, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 7, 2026 |
| TD Cowen | Buy | Buy | Maintain | Apr 8, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 8, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Feb 25, 2026 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Sep 29, 2025 |
| B of A Securities | Buy | Buy | Maintain | Aug 6, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 5, 2025 |
| Northland Capital Markets | Outperform | Outperform | Maintain | Aug 5, 2025 |
| Craig-Hallum | Buy | Hold | Upgrade | Aug 5, 2025 |
| Citizens Capital Markets | Market Outperform | Market Outperform | Maintain | Feb 26, 2025 |
| Baird | Outperform | Outperform | Maintain | Dec 6, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | May 10, 2023 |
| Imperial Capital | In Line | In Line | Maintain | May 18, 2020 |
| Ladenburg Thalmann | Neutral | Buy | Downgrade | Oct 15, 2018 |
| CL King | Neutral | Buy | Downgrade | Mar 16, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $420.37. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $561 | $383.09 | +33.5% | Oct 20, 2026 |
| Raymond James | Analyst unavailable | $675 | $402.87 | +60.6% | Oct 15, 2026 |
| Argus Research | Analyst unavailable | $600 | $506.98 | +42.7% | Sep 3, 2026 |
| Morgan Stanley | Meta Marshall | $640 | $528.41 | +52.2% | Aug 6, 2026 |
| Goldman Sachs | Analyst unavailable | $715 | $561.47 | +70.1% | Aug 6, 2026 |
| Piper Sandler | Analyst unavailable | $732 | $551.4 | +74.1% | Aug 6, 2026 |
| Barclays | Analyst unavailable | $688 | $609.49 | +63.7% | Aug 6, 2026 |
| Piper Sandler | Analyst unavailable | $724 | $565.8 | +72.2% | Jul 13, 2026 |
| Needham | Analyst unavailable | $750 | $597.04 | +78.4% | Jul 6, 2026 |
| Piper Sandler | James Fish | $674 | $457.33 | +60.3% | Jun 15, 2026 |
| Barclays | Tim Long | $523 | $426.89 | +24.4% | May 8, 2026 |
| Morgan Stanley | Analyst unavailable | $600 | $433.82 | +42.7% | May 7, 2026 |
| Goldman Sachs | Analyst unavailable | $535 | $434.5 | +27.3% | May 7, 2026 |
| UBS | Analyst unavailable | $440 | $416.57 | +4.7% | May 7, 2026 |
| Morgan Stanley | Analyst unavailable | $675 | $391.53 | +60.6% | Apr 8, 2026 |
| Goldman Sachs | Analyst unavailable | $625 | $391.53 | +48.7% | Apr 8, 2026 |
| Robert W. Baird | Analyst unavailable | $800 | $523.63 | +90.3% | Feb 25, 2026 |
| Craig-Hallum | Jeremy Hamblin | $820 | $543.47 | +95.1% | Feb 25, 2026 |
| RBC Capital | David Paige | $735 | $543.24 | +74.8% | Feb 25, 2026 |
| Piper Sandler | James Fish | $690 | $548.22 | +64.1% | Feb 25, 2026 |
| Northcoast Research | Keith Housum | $742 | $591.16 | +76.5% | Jan 6, 2026 |
| Morgan Stanley | Meta Marshall | $713 | $555.06 | +69.6% | Dec 17, 2025 |
| RBC Capital | Analyst unavailable | $860 | $554.37 | +104.6% | Nov 17, 2025 |
| Piper Sandler | James Fish | $753 | $622.38 | +79.1% | Nov 5, 2025 |
| Raymond James | Analyst unavailable | $855 | $867.12 | +103.4% | Aug 5, 2025 |
| Northland Securities | Michael Latimore | $800 | $867.12 | +90.3% | Aug 5, 2025 |
| Needham | Joshua Reilly | $870 | $867.12 | +107.0% | Aug 5, 2025 |
| UBS | Analyst unavailable | $840 | $867.12 | +99.8% | Aug 5, 2025 |
| Craig-Hallum | Analyst unavailable | $900 | $867.12 | +114.1% | Aug 5, 2025 |
| Morgan Stanley | Meta Marshall | $885 | $729.62 | +110.5% | Jul 11, 2025 |
| Barclays | Analyst unavailable | $726 | $506.96 | +72.7% | Feb 27, 2025 |
| Morgan Stanley | Meta Marshall | $700 | $636.39 | +66.5% | Dec 3, 2024 |
| Needham | Joshua Reilly | $525 | $443.98 | +24.9% | Oct 22, 2024 |
| Goldman Sachs | Michael Ng | $441 | $443.98 | +4.9% | Oct 22, 2024 |
| Robert W. Baird | William Power | $400 | $364.39 | -4.8% | Sep 10, 2024 |
| Craig-Hallum | Jeremy Hamblin | $370 | $315.35 | -12.0% | May 7, 2024 |
| Needham | Joshua Reilly | $400 | $311.27 | -4.8% | Apr 10, 2024 |
| Argus Research | John Staszak | $380 | $306.78 | -9.6% | Mar 13, 2024 |
| Credit Suisse | Sami Badri | $300 | $225.13 | -28.6% | Apr 11, 2023 |
| Morgan Stanley | Analyst unavailable | $155 | $168.59 | -63.1% | Dec 13, 2022 |
Track every rating change on AXON the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAxon Enterprise, Inc., founded in 1993 and headquartered in Scottsdale, Arizona, was previously known as TASER International, Inc. until its rebranding in April 2017. The company specializes in the development, production, and sale of conducted energy devices (CEDs) marketed under its well-known TASER brand, catering to both domestic and international clients. Axon's operations are divided into two primary segments: TASER, and Software and Sensors. In addition to its signature TASER devices, such as the TASER 7, X26P, X2, and consumer models, along with their corresponding cartridges, Axon offers an extensive portfolio of hardware and cloud-based software.…
Historical context
All AXON earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FIX Comfort Systems USA, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.2% | -8.5% | Comfort Systems USA: Strong Growth, Record Backlog, Margin Watchpoints |
| BE Bloom Energy Corporation | FY2026 Q3 · Calendar Q4 2026 | +36.0% | -8.7% | Bloom Energy Raises Outlook as AI Power Demand Drives Expansion |
| SNA Snap-on Incorporated | FY2026 Q3 · Calendar Q4 2026 | -5.9% | -3.4% | Snap-on: C&I strength offsets organic sales pressure in Q3 |
| HON Honeywell International Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.6% | +1.7% | Honeywell Raises 2026 Outlook as Backlog and Forge Support Growth |
| LMT Lockheed Martin Corporation | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +7.0% | Lockheed Martin: backlog and guidance rise, with execution risks |
| NSC Norfolk Southern Corporation | FY2026 Q3 · Calendar Q4 2026 | +4.6% | +3.1% | Norfolk Southern posts strong Q3 as capex outlook rises |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the AXON recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-11T06:39:45.180704+00:00
- Polygon adjusted daily market bars · 2026-10-24T15:00:42.871002+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T15:00:42.868076+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.